UnknownPhase 1

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.

Lead sponsor

Luye Pharma Group Ltd.

Asset

LY03017

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-45

Primary endpoint

•Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDLY03017/CT-CHN-101

NCT IDNCT06388551

Timeline

Milestones

Study first posted2024-04-29actual

Last update posted2024-04-29actual

Study start2024-05-10estimated

Primary completion2025-03-30estimated

Study completion2025-03-30estimated

Assets

Drug assets

LY03017

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age45 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Subject who voluntarily participate and sign the informed consent form.

•Healthy male/female volunteers aged ≥18 and ≤ 45 years.

•Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) ≥18.5 and < 26.0 kg/m2.

•Able to comply with the lifestyle restrictions

Exclusion criteria

•Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution.

•Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results.

•Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects.

•Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial.

•Subject has abnormal vital signs, laboratory abnormalities, and ECGs.

•Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing.

•Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust).

•Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results.

•Subject has a history of substance abuse within 1 year or a positive urine drug screen.

•Subject who has daily smoking of ≥ 5 cigarettes within 3 months.

•Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia.

•Subject who has consumption of special diet (such as grapefruit, chocolate, coffee, xanthine-rich foods/drinks) within 48 hours prior to dosing and/or subject who has excessive daily consumption of tea, coffee, grapefruit juice, caffeinated beverages for nearly 3 months.

•Subject who has participated in other clinical trials within 3 months before administration.

•Subject has used blood products or being blood donor or blood loss within 3 months.

•Pregnant, lactating women, or positive pregnancy test.

•Subject who refusal to contraception, or plan to donate sperm or ovums.

•Subject who has a history of needle or blood faintness.

•Subject directly involved in this clinical trial.

•Poor compliance or other conditions which would make participation in the study unsuitable.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other (unclassified)

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

Time frame:up to 216 hours

event count, event

Secondary/protocol endpoint

Maximum observed concentration (Cmax) of LPM526000133 in plasma

Time frame:up to 216 hours

concentration, descriptive

Secondary/protocol endpoint

Time to maximum observed concentration (Tmax) of LPM526000133 in plasma

Time frame:up to 216 hours

time to event, event

Secondary/protocol endpoint

Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of LPM526000133 in plasma

Time frame:up to 216 hours

concentration, descriptive

Secondary/protocol endpoint

Apparent terminal elimination half-life (t1/2) of LPM526000133 in plasma

Time frame:up to 216 hours

concentration, descriptive

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of LPM526000133 in plasma

Time frame:up to 216 hours

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.